Understanding the economic impact of leishmaniasis on households in endemic countries: a systematic review

References

• World Health Organization. Integratting NTDs into Global Health and Development. WHO/HTM/NT. Geneva: World Health Organization; 2017.
   Google Scholar
• Pascual Martínez F, Picado A, Roddy P, et al. Low castes have poor access to visceral leishmaniasis treatment in Bihar, India. Trop Med Int Heal. Wiley/Blackwell. 2012;17:666–673.
   PubMed Web of Science ®Google Scholar
• Boelaert M, Meheus F, Sanchez A, et al. The poorest of the poor: A poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop Med Int Heal. 2009;14:639–644. .
   PubMed Web of Science ®Google Scholar
• Berry I, Berrang-Ford L. Leishmaniasis, conflict, and political terror: A spatio-temporal analysis. Soc. Sci. Med. 2016 Oct;167:140-149.
   Google Scholar
• Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873–882.
   PubMed Web of Science ®Google Scholar
• Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;6736:1–20.
   Google Scholar
• Desjeux P. Leishmaniasis: public health aspects and control. Clin Dermatol. 1996;14:417–423.
   PubMed Web of Science ®Google Scholar
• Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis : current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2:494–501.
   PubMed Web of Science ®Google Scholar
• Singh OP, Hasker E, Boelaert M, et al. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis. Elsevier Ltd. 2016;16:e304–e309.
   PubMedGoogle Scholar
• Mondal D, Singh SP, Kumar N, et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis. 2009;3. DOI:10.1371/journal.pntd.0000355
   PubMed Web of Science ®Google Scholar
• National Vector Borne Disease Control Programme India. Kala Azar situation in India [Internet]. [ cited 2018 Jun 1]. Available from: http://www.nvbdcp.gov.in/index4.php?lang=1&level=0&linkid=467&lid=3750
   Google Scholar
• Al-Salem W, Herricks JR, Hotez PJ. A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries. Parasit Vectors. 2016;9. DOI:10.1186/s13071-016-1743-7
   PubMed Web of Science ®Google Scholar
• Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21:334–359.
   PubMed Web of Science ®Google Scholar
• Burza S, Mahajan R, Sanz MG, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis. 2014;59:552–555.
   PubMed Web of Science ®Google Scholar
• Diro E, Lynen L, Ritmeijer K, et al. Visceral leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis. 2014;8. DOI:10.1371/journal.pntd.0002869
   Web of Science ®Google Scholar
• Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis. 2008;2. DOI:10.1371/journal.pntd.0000313
   PubMed Web of Science ®Google Scholar
• Murray CJL, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015;386:2145–2191.
   PubMed Web of Science ®Google Scholar
• Murray N, Kassebaum NJ, Arora M, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1603–1658.
   PubMed Web of Science ®Google Scholar
• Bennis I, Belaid L, De Brouwere V, et al. “The mosquitoes that destroy your face”. Social impact of cutaneous leishmaniasis in South-eastern Morocco, A qualitative study. Fortin A, editor. PLoS One. Public Library of Science. 2017;12:e0189906.
   PubMed Web of Science ®Google Scholar
• Bailey F, Mondragon-Shem K, Hotez P, et al. A new perspective on cutaneous leishmaniasis—implications for global prevalence and burden of disease estimates. Jaffe CL, editor. PLoS Negl Trop Dis. Public Library of Science. 2017;11:e0005739.
   PubMed Web of Science ®Google Scholar
• Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006;22:552–557.
   PubMed Web of Science ®Google Scholar
• Bern C, Courtenay O, Alvar J. Of cattle, sand flies and men: A systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Negl Trop Dis. 2010;4. DOI:10.1371/journal.pntd.0000599
   Web of Science ®Google Scholar
• Argaw D, Mulugeta A, Herrero M, et al. Risk factors for visceral leishmaniasis among residents and migrants in Kafta-Humera, Ethiopia. PLoS Negl Trop Dis. 2013;7:e2543.
   PubMed Web of Science ®Google Scholar
• Thakur C. Socio-economics of visceral leishmaniasis in Bihar (India). Trans R Soc Trop Med Hyg. 2000;94:156–157.
   PubMed Web of Science ®Google Scholar
• Nackers F, Mueller YK, Salih N, et al. Determinants of visceral leishmaniasis: A case-control study in Gedaref State, Sudan. PLoS Negl Trop Dis. 2015;9:1–16.
   Web of Science ®Google Scholar
• Hasker E, Singh SP, Malaviya P, et al. Management of visceral leishmaniasis in rural primary health care services in Bihar, India. Trop Med Int Health. 2010;15(Suppl 2):55–62.
   PubMedGoogle Scholar
• Sunyoto T, Adam GK, Atia AM, et al. “Kala-Azar is a dishonest disease”: community perspectives on access barriers to visceral leishmaniasis (Kala-Azar) diagnosis and care in Southern Gadarif, Sudan. Am J Trop Med Hyg. 2018;98. DOI:10.4269/ajtmh.17-0872
   PubMed Web of Science ®Google Scholar
• Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: A multicountry analysis. Lancet. 2003;362:111–117.
   PubMed Web of Science ®Google Scholar
• Rice DP. Cost-of-illness studies: fact or fiction? Lancet (London, England). Elsevier. 1994;344:1519–1520.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• PROSPERO International prospective register of systematic reviews [Internet]. [ cited 2018 Feb 19]. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=88950
   Google Scholar
• Berman P, Kendall C, Bhattacharyya K. The household production of health: integrating social science perspectives on micro-level health determinants. Soc Sci Med. 1994;38:205–215.
   PubMed Web of Science ®Google Scholar
• Ekman B. Catastrophic health payments and health insurance: some counterintuitive evidence from one low-income country. Health Policy (New York). Elsevier. 2007;83:304–313.
   Web of Science ®Google Scholar
• Kawabata K, Xu K, Carrin G. Preventing impoverishment through protection against catastrophic health expenditure. Bull World Health Organ. World Health Organization. 2002;80:612.
   PubMed Web of Science ®Google Scholar
• Alam K, Mahal A. Economic impacts of health shocks on households in low and middle income countries: a review of the literature. Global Health. 2014;10:21.
   PubMed Web of Science ®Google Scholar
• Ranson MK. Reduction of catastrophic health care expenditures by a community-based health insurance scheme in Gujarat, India: current experiences and challenges. Bull World Health Organ. 2002;80:613–621.
   PubMed Web of Science ®Google Scholar
• van Doorslaer E, O’Donnell O, Rannan-Eliya RP, et al. Catastrophic payments for health care in Asia. Health Econ. Wiley-Blackwell. 2007;16:1159–1184.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ Econ Eval Working Party BMJ. 1996;313:275–283.
   PubMed Web of Science ®Google Scholar
• Molinier L, Bauvin E, Combescure C, et al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value in Health 2008;11(5):878–885
   PubMed Web of Science ®Google Scholar
• Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327.
   PubMedGoogle Scholar
• Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996;10:460–466.
   PubMed Web of Science ®Google Scholar
• World Bank. Inflation, consumer prices (annual %) [Internet]. [ cited 2018 Jun 1]. Available from: https://data.worldbank.org/indicator/fp.cpi.totl.zg
   Google Scholar
• World Bank. Official exchange rate (LCU per US$, period average) [Internet]. [ cited 2018 Jun 1]. Available from: https://data.worldbank.org/indicator/pa.nus.fcrf
   Google Scholar
• Adhikari S, Maskay N. Economic cost and consequences of Kala-Azar in Danusha and Mahottari districts of Nepal. Indian J Community Med. 2005;30:121–125.
   Google Scholar
• Rijal S, Koirala S, Van der Stuyft P, et al. The economic burden of visceral leishmaniasis for households in Nepal. Trans R Soc Trop Med Hyg. 2006;100:838–841.
   PubMed Web of Science ®Google Scholar
• Adhikari SR, Maskay NM, Sharma BP. Paying for hospital-based care of Kala-azar in Nepal: assessing catastrophic, impoverishment and economic consequences. Health Policy Plan. 2009;24:129–139.
   PubMed Web of Science ®Google Scholar
• Sharma B, Maskay N, Adhikari S, et al. Socio-economic determinants of Kala-azar in Nepal. J Nepal Health Res Counc. 2004;2:58–65.
   Google Scholar
• Uranw S, Meheus F, Baltussen R, et al. The household costs of visceral leishmaniasis care in South-eastern Nepal. PLoS Negl Trop Dis. 2013;7. DOI:10.1371/journal.pntd.0002062
   PubMed Web of Science ®Google Scholar
• Sundar S, Arora R, Singh SP, et al. Household cost-of-illness of visceral leishmaniasis in Bihar, India. Trop Med Int Heal. 2010;15:50–54.
   PubMed Web of Science ®Google Scholar
• Sarnoff R, Desai J, Desjeux P, et al. The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India. Trop Med Int Heal. 2010;15:42–49.
   PubMed Web of Science ®Google Scholar
• Meheus F, Boelaert M, Baltussen R, et al. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Heal. 2006;11:1715–1724.
   PubMed Web of Science ®Google Scholar
• Anoopa Sharma D, Bern C, Varghese B, et al. The economic impact of visceral leishmaniasis on households in Bangladesh. Trop Med Int Heal. Blackwell Publishing Ltd. 2006;11:757–764.
   PubMed Web of Science ®Google Scholar
• Ozaki M, Islam S, Rahman KM, et al. Economic consequences of post-kala-azar dermal leishmaniasis in a rural Bangladeshi community. Am J Trop Med Hyg. 2011;85:528–534.
   PubMed Web of Science ®Google Scholar
• de Carvalho IPSF, Peixoto HM, Romero GAS, et al. Cost of visceral leishmaniasis care in Brazil. Trop Med Int Heal. 2017;22:1579–1589.
   PubMed Web of Science ®Google Scholar
• de Assis TSM, Rosa DCP, Teixeira EDM, et al. The direct costs of treating human visceral leishmaniasis in Brazil. Rev Soc Bras Med Trop. 2017;50:478–482.
   PubMed Web of Science ®Google Scholar
• Meheus F, Abuzaid AA, Baltussen R, et al. The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs. Am J Trop Med Hyg. 2013;89:1146–1153. .
   PubMed Web of Science ®Google Scholar
• Tachfouti N, Najdi A, Alonso S, et al. Cost of pediatric visceral leishmaniasis care in Morocco. Kirk M, editor. PLoS One. Public Library of Science. 2016;11:e0155482.
   PubMed Web of Science ®Google Scholar
• Adhikari SR, Maskay NM. The economic burden of Kala-azar in households of the Danusha and Mahottari districts of Nepal. Acta Trop. 2003;88:1–2.
   PubMed Web of Science ®Google Scholar
• Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ. 2005;83:394–395.
   PubMed Web of Science ®Google Scholar
• Wagstaff A, Flores G, Hsu J, et al. Progress on catastrophic health spending in 133 countries: a retrospective observational study. Lancet Glob Heal. Elsevier. 2018;6:e169–e179.
   PubMed Web of Science ®Google Scholar
• Sauerborn R, Adams A, Hien M. Household strategies to cope with the economic costs of illness. Soc Sci Med Pergamon. 1996;43:291–301.
   PubMed Web of Science ®Google Scholar
• Ahluwalia I, Bern C, Costa C, et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg. 2003;69:624–628.
   PubMed Web of Science ®Google Scholar
• Houweling TAJ, Karim-Kos HE, Kulik MC, et al. Socioeconomic inequalities in neglected tropical diseases: a systematic review. Knopp S, editor. PLoS Negl Trop Dis. Public Library of Science. 2016;10:e0004546.
   PubMed Web of Science ®Google Scholar
• Den Boer M, Argaw D, Jannin J, et al. Leishmaniasis impact and treatment access. Clin Microbiol Infect. 2011;17:1471–1477.
   PubMed Web of Science ®Google Scholar
• Sunyoto T, Adam GK, Atia AM, et al. “Kala-Azar is a dishonest disease”: community perspectives on access barriers to visceral leishmaniasis (Kala-Azar) diagnosis and care in Southern Gadarif, Sudan. Am J Trop Med Hyg. 2018;98:1091–1101. .
   PubMed Web of Science ®Google Scholar
• Boettcher JP, Siwakoti Y, Milojkovic A, et al. Visceral leishmaniasis diagnosis and reporting delays as an obstacle to timely response actions in Nepal and India. BMC Infect Dis. 2015;15:1–14.
   PubMed Web of Science ®Google Scholar
• Gerstl S, Amsalu R, Ritmeijer K. Accessibility of diagnostic and treatment centres for visceral leishmaniasis in Gedaref State, northern Sudan. Trop Med Int Heal. 2006;11:167–175.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2010;22–26. DOI:10.1038/nrmicro1766
   Web of Science ®Google Scholar
• Sunyoto T, Verdonck K, El Safi S, et al. Uncharted territory of the epidemiological burden of cutaneous leishmaniasis in sub-Saharan Africa—A systematic review. PLoS Negl Trop Dis. 2018;12:e0006914.
   PubMed Web of Science ®Google Scholar
• Ramdas S. Cruel disease, cruel medicine: self-treatment of cutaneous leishmaniasis with harmful chemical substances in Suriname. Soc Sci Med. Elsevier Ltd. 2012;75:1097–1105.
   PubMed Web of Science ®Google Scholar
• Bennis I, De Brouwere V, Belrhiti Z, et al. Psychosocial burden of localised cutaneous leishmaniasis: A scoping review. BMC Public Health. 2018;18:1–12.
   Web of Science ®Google Scholar
• van Griensven J, Gadisa E, Aseffa A, et al. Treatment of cutaneous leishmaniasis caused by Leishmania aethiopica: a systematic review. PLoS Negl Trop Dis. 2016;10:1–20.
   Web of Science ®Google Scholar
• Gonzalez U, Pinart M, Reveiz L, et al. Interventions for old world cutaneous leishmaniasis. [Review] [156 refs]. Cochrane Database Syst Rev. 2008;CD005067. DOI:10.1002/14651858.CD005067.pub3.Copyright
   PubMed Web of Science ®Google Scholar
• Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of tropical medicine and hygiene (ASTMH). Am J Trop Med Hyg. 2017;96:24–45.
   PubMed Web of Science ®Google Scholar
• Handler MZ, Patel PA, Kapila R, et al. Cutaneous and mucocutaneous leishmaniasis: clinical perspectives. J Am Acad Dermatol. Elsevier Inc. 2015;73:897–908.
   PubMed Web of Science ®Google Scholar
• Chappuis F, Rijal S, Jha UK, et al. Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal. Trop Med Int Heal. 2006;11:31–40.
   PubMed Web of Science ®Google Scholar
• Russell S. Illuminating cases: understanding the economic burden of illness through case study household research. Health Policy Plan. Oxford University Press. 2005;20:277–289.
   PubMed Web of Science ®Google Scholar
• WHO. Kala-azar elimination programme: report of a WHO consultation of partners Geneva, Switzerland 10–11 February 2015. World Heal Organ Geneva. 2015;1–33.
   Google Scholar
• World Health Organization. Investing to overcome the global impact of neglected tropical diseases third WHO report on neglected tropical diseases department of control of neglected tropical diseases. Geneva: WHO; 2015.
   Google Scholar
• de Vlas SJ, Stolk WA, le Rutte EA, et al. Concerted efforts to control or eliminate neglected tropical diseases: how much health will be gained? Liang S, editor. PLoS Negl Trop Dis. Public Library of Science. 2016;10:e0004386.
   PubMed Web of Science ®Google Scholar
• Lenk EJ, Redekop WK, Luyendijk M, et al. Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. Budke CM, editor. PLoS Negl Trop Dis. Public Library of Science. 2018;12:e0006250.
   PubMed Web of Science ®Google Scholar
• Alves F, Bilbe G, Blesson S, et al. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev. 2018;31:e00048–e18.
   PubMed Web of Science ®Google Scholar
• Sunyoto T, Potet J, Boelaert M. Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most. BMJ Glob Heal. 2018;3:e000709.
   PubMed Web of Science ®Google Scholar
• WHO. WHO and gilead sciences extend collaboration against visceral leishmaniasis [Internet]. [ cited 2018 Sep 17]. Available from: http://www.who.int/neglected_diseases/news/WHO_and_Gilead_Sciences_extend_collaboration/en/
   Google Scholar
• Gaspani S. Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx. Generics Biosimilars Initiat J. 2013;2:60–62.
   Google Scholar
• Balasegaram M, Ritmeijer K, Lima MA, et al. Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs. 2012;17:493–510.
   PubMed Web of Science ®Google Scholar